The anti-inflammatory role of heme oxygenase-1 in lipopolysaccharide and cytokine-stimulated inducible nitric oxide synthase and nitric oxide production in human periodontal ligament cells

J Periodontol. 2009 Dec;80(12):2045-55. doi: 10.1902/jop.2009.090145.

Abstract

Background: Although heme oxygenase-1 (HO-1) is involved in anti-inflammation, the mechanisms of its activity in regulating periodontal inflammation are largely unclear. Therefore, the aim of this study is to investigate the anti-inflammatory properties of HO-1 in lipopolysaccharide (LPS)- and proinflammatory cytokine-stimulated inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production in human periodontal ligament (PDL) cells.

Methods: PDL cells were treated with LPS plus a combination of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in serum-free media for 1 day. The production of NO was evaluated using a Griess reagent kit. The expression of iNOS and HO-1 proteins and mRNAs was evaluated using Western blotting and reverse transcriptase-polymerase chain reaction, respectively.

Results: Proinflammatory cytokines and LPS triggered iNOS and HO-1 expression and NO production in PDL cells. HO-1 inhibitor and HO-1 small interfering RNA (siRNA) attenuated the LPS- and cytokine-stimulated NO release and iNOS and HO-1 expression. Specific inhibitors of p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases phosphatidylinositol 3-kinase (PI3K), nuclear factor-kappa B (NF-kappaB), and protein kinase C delta (PKC-delta) greatly reduced the levels of iNOS and HO-1 expression induced by LPS plus cytokines.

Conclusions: Collectively, these data suggested that HO-1 inhibition blocked LPS- and proinflammatory cytokine-stimulated iNOS expression and NO production in PDL cells via a mechanism that involves p38, ERK, PI3K, NF-kappaB, and PKC-delta. Thus, the regulation of HO-1 activity may be a therapeutic strategy for periodontal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Cell Line
  • Cells, Cultured
  • Enzyme Activation / drug effects
  • Enzyme Induction
  • Enzyme Inhibitors / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Heme Oxygenase (Decyclizing) / antagonists & inhibitors
  • Heme Oxygenase-1 / antagonists & inhibitors
  • Heme Oxygenase-1 / drug effects
  • Heme Oxygenase-1 / physiology*
  • Humans
  • Interleukin-1beta / pharmacology*
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Lipopolysaccharides / pharmacology*
  • Metalloporphyrins / pharmacology
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • NF-kappa B / antagonists & inhibitors
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / drug effects*
  • Periodontal Ligament / drug effects*
  • Periodontal Ligament / enzymology
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase C-delta / antagonists & inhibitors
  • Protoporphyrins / pharmacology
  • RNA, Small Interfering / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Enzyme Inhibitors
  • Interleukin-1beta
  • Lipopolysaccharides
  • Metalloporphyrins
  • NF-kappa B
  • Phosphoinositide-3 Kinase Inhibitors
  • Protoporphyrins
  • RNA, Small Interfering
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • cobaltiprotoporphyrin
  • tin protoporphyrin IX
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
  • Heme Oxygenase (Decyclizing)
  • Heme Oxygenase-1
  • Protein Kinase C-delta
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases